When this pandemic first began, it quickly became clear that we didn’t just need vaccines, we’d also needed vaccinations, and lots of them. Until people in all corners of the world – not just those that could afford it – were protected, the virus would continue to rage. In an unprecedented show of global solidarity, the world came together to back COVAX, a unique global solution aimed at making equitable access to COVID-19 vaccines possible. Today, however, the world is failing COVAX, despite the initiative – under the leadership of Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization – having demonstrated that its model works and despite having the support of 192 governments.

People in 122 economies have already received COVAX doses, more than 58 million of them. By the end of the year, the program will have delivered at least 1.3 billion doses, and possibly 1.8 billion by early 2022, to people in 92 lower-income countries who would otherwise have limited or no access to them. But we can and need to get there quicker. Research commissioned by COVAX suggests that while a third of people in the wealthiest countries have now had their first dose, so far just 0.2% of people in lower-income countries have received any. Supply bottlenecks are a problem for many countries, but at a global level, right now the issue isn’t that there aren’t enough doses to go around – it’s just that they aren’t going around.

Governments clearly recognize the need for equitable access and support the principle that ability to pay should not determine whether someone is protected from this virus – that’s shown through their support and funding of COVAX. And yet, we continue to see action taken by individual governments at the domestic level such as export bans and dose hoarding that are hindering efforts to end the pandemic at the global level.

One of the motivations for creating COVAX was to avoid a repeat of what happened in 2009, during the swine-flu pandemic, when the majority of vaccines ended up in the possession of only a small number of high-income countries. The COVAX Advance Market Commitment, or AMC, solves this by creating a way for doses to be procured for lower-income countries, funded largely through contributions from wealthier countries as well as philanthropic institutions.

COVAX also put in place incentives to ensure manufacturers could produce doses at scale the moment they were authorized, as well as ensuring that important no-fault compensation, indemnification and liability legal safety nets were in place. COVAX has also worked with lower-income countries, many of which have had their already weak health systems disrupted by the pandemic, to ensure they have the supply and cold chains in place to ready deliver these vaccines when ready.

Rodrigo Sura—EPA-EFE/Shutterstock
A nurse applies the vaccine against COVID-19 during a day of vaccination to health personnel in a Public Health Unit in Mejicanos, El Salvador on March 12, 2021. Personnel from the Ministry of Health of El Salvador began the distribution of vaccines against the SARS-CoV-2 coronavirus, whose cargo of 33,600 doses arrived in the country a night earlier, and is the first donated under the Covax system of the World Health Organization.
Rodrigo Sura—EPA-EFE/Shutterstock

 But global access to vaccines is not happening fast enough, and it’s in everyone’s interest that we get there sooner. The longer it takes to protect people most at risk, such as health and social care workers and vulnerable people, the longer the virus will continue to circulate and the greater the risk that new and potentially more dangerous variants will emerge. Moreover, any delay will also prolong the economic misery, by ensuring that efforts to resume commerce, trade and travel continue to stall.

Only governments have the power to speed things up now, by turning their commitment to COVAX into action, and there are four keys to make this happen.

To find out what these four ways are read the original article on TIME.com.

TOPICS: COVID-19COVAXInnovation

Subscribe to our newsletter